Pharma business models, pipelines, and patent cliffs

How a large pharma company actually makes money

Strip away the science and a pharma company's economics look deceptively simple: it sells patent-protected drugs at a price that reflects the value they create, for as long as competition can't legally copy them, and it reinvests a meaningful share of that revenue into researching the next generation of drugs to replace the ones that will eventually lose that protection. The entire business model is built around a temporary monopoly window granted by a patent, and everything distinctive about how pharma companies are run, valued, and acquired traces back to what happens when that window closes.

This is different from almost every other sector a generalist candidate has studied. A consumer brand's competitive advantage, once built, tends to decay slowly and can often be renewed through marketing and product refreshes. A pharma company's competitive advantage on any single product has a known, legally defined expiration date, and no amount of marketing spend extends it past that date. That certainty, oddly, is what makes patent expiration such a predictable and heavily modeled event rather than a surprise: everyone in the market, the company, its competitors, and the bankers covering it, knows years in advance exactly when a given drug's protection runs out.

The pipeline is the real asset

Because any single product's revenue has a visible expiration date, a pharma company's long-term value depends less on what it's selling today and more on what it will have ready to sell once today's best sellers go off patent. That pipeline, the portfolio of drug candidates working through discovery and clinical development, is the asset that actually determines whether a pharma company grows, stagnates, or shrinks over the next decade.

This is why large pharma companies spend heavily on research and development and, just as importantly, why they're such active acquirers and licensors of other companies' pipelines. Internal research is slow, expensive, and has no guarantee of producing a successful candidate on any particular timeline, while a promising drug candidate sitting inside a smaller biotech is already partway through that process and can be evaluated on real data rather than a research thesis. A large company weighing whether to build a pipeline asset internally or acquire one externally is really weighing time and certainty against cost, and it's a decision pharma companies make constantly, at every stage of a product's development. The mechanics of how those external deals get structured, particularly the licensing and milestone-based deals that let a large company access a promising asset without buying the whole company outright, are covered in healthcare deal structures: licensing and milestones.

Valuing the pipeline itself, especially the pre-approval portion still working through clinical trials, requires the risk-adjusted approach covered in how biotech companies are valued: each candidate is worth its eventual commercial potential multiplied by the probability it actually gets there, summed across the whole pipeline. A large pharma company's total value, in this framework, is really the sum of its already-marketed products, each declining toward its own patent expiration, plus its pipeline of future products, each with its own probability of eventually replacing that declining revenue.

The patent cliff, mechanically

A patent cliff is the point at which a drug's period of exclusivity ends and competition is legally allowed to enter, and the revenue effect is typically fast and severe rather than gradual. Once a small-molecule drug's exclusivity ends, generic manufacturers can produce and sell chemically identical versions, and because a generic doesn't need to repeat the original drug's expensive clinical trials to prove safety and efficacy, generics can be priced far below the original branded price almost immediately. Patients and payors, who have every incentive to prefer the cheaper option once it's proven equivalent, switch quickly, and the branded product's sales can fall sharply within a short window after the cliff hits.

Biologic drugs face a softer version of the same cliff. Because a biologic is manufactured from living cells rather than synthesized chemically, a competitor can't produce an exact generic copy, only a biosimilar, a highly similar but not molecule-for-molecule identical version that goes through its own separate, somewhat more involved regulatory pathway. That extra complexity generally makes biosimilar erosion slower and less complete than small-molecule generic erosion, though it still represents a real and significant loss of exclusivity-driven pricing power once it occurs.

The reason interviewers ask about patent cliffs so often is that the concept ties together almost everything else in this guide. It's the reason large pharma companies are such active acquirers of biotech pipelines, since replacing revenue that's scheduled to disappear on a known date is a constant, structural need rather than an occasional opportunity. It's the reason a company's current revenue can be a poor guide to its future value, since a large share of today's sales might be walking toward a cliff a few years out. And it's the reason sum-of-the-parts valuation matters so much in this sector: a pharma company's blended growth rate hides a story that's really two stories, a shrinking base of maturing products and a set of newer products and pipeline candidates meant to offset that decline.

Build versus buy, and why buy usually wins on timing

A large pharma company facing an approaching patent cliff has, broadly, two ways to replace the revenue: invest more heavily in its own internal research, or acquire or license an asset that's already further along in another company's pipeline. Internal research has the advantage of full ownership and, if it works, the highest possible return, but it comes with long timelines and a real chance of failure at every stage along the way, and a large company can't always wait out a full research cycle before its existing products start declining. Acquiring or licensing an external asset costs more upfront, since the seller has already absorbed some of the early-stage risk and prices that risk reduction into the deal, but it compresses the timeline and lets a buyer evaluate real clinical data rather than a research thesis before committing.

This tradeoff is a big part of why pharma M&A and licensing activity is a structural, ongoing feature of the sector rather than an occasional event tied to any particular market cycle. Every large pharma company is managing a portfolio of products at different points on their own individual patent-expiration timelines, and the pipeline gap left by any one product's eventual cliff has to be filled from somewhere, internal research, external acquisition, or licensing, well before that cliff actually arrives.

A simplified, purely hypothetical illustration makes the tradeoff concrete. Suppose a pharma company has a top product generating $1 billion of annual revenue today, with a patent cliff arriving in a few years and a hypothetical 80% of that revenue expected to erode within the following year or two once generic competition enters. The company could fund additional internal research aimed at a replacement, accepting years of uncertain, potentially fruitless spending, or it could acquire a smaller company with a similar-sized asset already in late-stage trials, paying a premium for the reduced timeline and reduced uncertainty. Neither choice is free of risk, but the acquisition converts an open-ended research bet into a more bounded, priceable one, which is exactly what a corporate development team is paid to evaluate.

Exclusivity is broader than just the patent

It's worth knowing that patent protection isn't the only barrier standing between a branded drug and generic or biosimilar competition, because interviewers sometimes test whether a candidate assumes "patent expiration" is the whole story. Regulatory exclusivity, granted separately by the approving regulator rather than through the patent system, can also delay competition, and it exists for reasons distinct from patent law, such as encouraging development of drugs for smaller patient populations or encouraging pediatric testing. A company's actual competition-free window is effectively the longer of its remaining patent life and any regulatory exclusivity still in force, and a sophisticated pipeline analysis has to track both, not just patent filings. This is also why patent litigation is its own distinct risk category in the sector: a generic manufacturer can challenge a branded company's patents before exclusivity would otherwise expire, seeking to enter the market earlier, and the outcome of that litigation is itself a real, sometimes binary, valuation input. That litigation risk, along with the other regulatory forces that sit on top of ordinary patent economics, is covered in regulatory risk in healthcare M&A.

Generics and specialty pharma: a different business model entirely

Not every company in the pharma sub-sector runs on the innovator model described above. A generics manufacturer doesn't discover new drugs at all; it competes on manufacturing scale, cost efficiency, and speed to market once a branded competitor's exclusivity has ended. Its growth comes from launching into other companies' patent cliffs rather than avoiding its own, and it gets valued much closer to an industrials or manufacturing business, on margins and volume, than to an innovator biopharma company being valued on pipeline potential. Specialty pharma companies sit somewhere in between: they typically focus on a narrower set of therapeutic areas or complex-to-manufacture products where competition is more limited even after formal exclusivity ends, which can soften their own version of the patent cliff without eliminating it. Recognizing which model a given company follows, innovator, generic, or specialty, is often the first fork in the road for figuring out how to value it and what questions to ask about its future, and it's the same fork covered from the top down in the healthcare sub-sector map.

Practice question

Why do large pharma companies spend so much on acquiring smaller biotech companies?

It comes down to the patent cliff. A pharma company's revenue is concentrated in a handful of patent-protected products, and each of those products has a known expiration date after which generic or biosimilar competition enters and revenue typically falls sharply. That means every large pharma company is constantly managing a pipeline gap: revenue it knows will decline on a specific timeline, and a need to replace it with new products before that decline actually happens. Building replacement products entirely through internal research is slow and carries real failure risk at every stage, and a company can't always wait out a full research cycle before its existing top sellers start eroding. Acquiring or licensing a promising asset from a smaller biotech compresses that timeline, because the target has often already cleared some of the riskiest early clinical stages and the buyer can evaluate real trial data instead of a research thesis. It costs more upfront than building it yourself would in a perfect world, but it converts a highly uncertain, multi-year internal bet into a more predictable, faster path to replacing revenue that's already scheduled to disappear. That's why pipeline-driven M&A and licensing activity is a permanent structural feature of the pharma sector rather than something that happens only occasionally.

What the interviewer is listening for: whether you connect the patent cliff directly to the M&A rationale, rather than giving a generic "companies buy other companies to grow" answer. A strong answer names the build-versus-buy tradeoff explicitly and shows you understand why timing, not just cost, drives the decision.